Sirin Olga, Park Frank
Department of Medicine, Program in Gene Therapy, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Gene. 2003 Dec 24;323:67-77. doi: 10.1016/j.gene.2003.09.006.
Methods to regulate gene expression in vitro and in vivo are currently areas of intense research. The present study, therefore, was designed to determine the efficacy of transgene expression using the GeneSwitch mifepristone-regulatable system within the context of an integrating HIV-1 vector. Lentiviral transfer plasmids expressing the red (DsRed2) and green fluorescent protein (EGFP) markers were constructed for in vitro assessment on the basal and mifepristone-induced cell activation levels by FACS analyses. In our design, efficient cell activation and transgene expression were found using a binary lentivector system i.e., the trans-activator, Switch, and the inducible promoter-transgene expression cassette were cloned into separate vectors. Note that the Switch trans-activator performed optimally when cloned into the reverse-orientation, but the inducible promoter containing lentivector did not appear to be dependent upon the orientation within the lentivector backbone. This binary lentivector system resulted in tightly regulated transgene expression, with low basal cell activation in the absence of mifepristone (MFP). Upon induction, a 41- to 275-fold increase in the number of DsRed2- and EGFP-positive cells were detected (n=3). To determine the inducing ability of the GeneSwitch, we cloned the human alpha(1)-antitrypsin cDNA into the optimal lentiviral vector and transduced HeLa and Huh7 cells at increasing lentivector doses as determined by p24 Gag ELISA. We found that MFP could induce the expression of hAAT protein in HeLa cells from 310 to 15,000 ng hAAT/10(6) cells/24 h, which was a 48-fold induction. Similar results were observed in huH7 cells. In all, this study demonstrates that the GeneSwitch system can be designed within the context of a lentiviral vector for in vitro gene transfer, and this may also provide a viable method for temporally regulating gene expression for therapeutic applications in vivo or ex vivo.
体外和体内调节基因表达的方法是当前的研究热点。因此,本研究旨在确定在整合型HIV-1载体背景下使用米非司酮可调节的基因开关系统进行转基因表达的效果。构建了表达红色(DsRed2)和绿色荧光蛋白(EGFP)标记的慢病毒转移质粒,通过流式细胞术分析对基础水平和米非司酮诱导的细胞激活水平进行体外评估。在我们的设计中,使用二元慢病毒载体系统发现了有效的细胞激活和转基因表达,即反式激活因子Switch和诱导型启动子-转基因表达盒被克隆到不同的载体中。请注意,当克隆到反向时,Switch反式激活因子表现最佳,但含有诱导型启动子的慢病毒载体似乎不依赖于慢病毒载体骨架内的方向。这种二元慢病毒载体系统导致转基因表达受到严格调控,在没有米非司酮(MFP)的情况下基础细胞激活水平较低。诱导后,检测到DsRed2和EGFP阳性细胞数量增加了41至275倍(n = 3)。为了确定基因开关的诱导能力,我们将人α1-抗胰蛋白酶cDNA克隆到最佳慢病毒载体中,并按照p24 Gag ELISA确定的增加的慢病毒载体剂量转导HeLa和Huh7细胞。我们发现MFP可以诱导HeLa细胞中hAAT蛋白的表达,从310 ng hAAT/10^6细胞/24小时增加到15,000 ng hAAT/10^6细胞/24小时,这是48倍的诱导。在Huh7细胞中也观察到了类似的结果。总之,本研究表明基因开关系统可以在慢病毒载体背景下设计用于体外基因转移,这也可能为体内或体外治疗应用中暂时调节基因表达提供一种可行的方法。